Aims-To determine whether lack ofMHC class II antigen and intercellular adhesion molecule-i (ICAM-1) expression in some tumours is due to the inability of the tumour cells to respond to the cytokine interferon-y (IFN-y), an important activator of these surface molecules. Methods-Cells from 40 colorectal tumours which did not constitutively express class II MHC antigens or ICAM-l were kept in short term culture after disaggregation for a few days to two weeks without significant loss of viability. These were treated with IFN-y. Expression of class II MHC antigens and ICAM-1 was determined using immunohistological techniques. Results-There was clear induction in vitro of both MHC class II antigens and ICAM-1 in cells from eight ofthe tumours, with between 50 and 80% of the tumour cells in the cultures staining positively. The staining was apparent within 24 hours, appeared maximal at about three days, and declined thereafter. There were no obvious differences in cell morphology or viability between the cultures which were inducible and those which were not, nor were there obvious differences between the tumours from which they were derived. Conclusions-Expression of MHC class II antigens and ICAM-l may be induced by IFN-y in a small proportion of colorectal tumours which do not constitutively express these antigens, showing that only a minority of tumours are capable of responding to this cytokine. 
There is accumulating evidence that tumours can express antigens which are recognised specifically in the context of major histocompatibility complex (MHC) antigens by T lymphocytes. The strongest evidence comes from the study of melanoma, where target antigens and MHC restriction elements have been identified.'2 Evidence for other tumours is less strong but indications are that renal cell carcinomas,3 lung carcinomas4 and colorectal car- cinomas," amongst others, express tumour antigens which are recognised specifically by T lymphocytes.
T lymphocyte recognition oftumour neo-antigens requires that these be complexed to MHC antigens in so-called MHC restricted recognition. 7 An alternative non-MHC restricted pathway exists which relies on cell adhesion molecules such as intercellular adhesion molecule-I (ICAM-1), a ligand for lymphocyte function as- Tumour cells lacking these molecules at their surfaces will not be recognised byT lymphocytes and so a potentially immunogenic tumour could avoid surveillance. Direct experimental evidence for this has been obtained from a number of mouse models. '3 14 Loss of class I MHC antigens (HLA A, B, C), normally expressed by bowel epithelium, is common in colorectal carcinoma, with either single alleles or occasionally all alleles missing."'-"' This loss of class I MHC antigen expression by human tumours has been taken as indirect evidence for antitumour mechanisms mediated by specific T The sections were rinsed and the secondary biotinylated rabbit antimouse antibody (Dako) added. Incubation with the ABC solution (Dako) followed, and the final chromagen was DAB (3,3' diaminobenzidine tetrachloride; BDH, Lutterworth, UK). The slides were counter-stained with Meyer's haematoxylin (BDH), before mounting in DPX (BDH). Frozen sections of human tonsil were used as positive controls throughout the staining procedures: for negative controls, the primary antibody was omitted. Histological confirmation and staging of tumours were carried out on paraffin wax sections stained with haematoxylin and eosin. All slides were assessed by the investigators and reported by experienced histopathologists (Dr J Crocker, Heartlands NHS Trust Hospital and Drs T Ashworth and K Chen, Walsgrave NHS Trust Hospital).
Results

TISSUE SAMPLES
Carcinoma was histologically confirmed in all 50 cases. Of these, six were well differentiated, 38 moderately differentiated, six poorly differentiated, and two of a mucinous type. In six cases the tumour was known to have metastasised to the liver at the time of surgery, in three the tumour was confined to the mucosa (Dukes' stage A), in 20 it had extended through the bowel wall (Dukes' stage B), and in 21 adjacent lymph nodes contained tumour deposits (Dukes' stage C). In six of the 50 cases there was evidence of a pronounced lympho- IFN-y by expressing MHC class II antigens and ICAM-1). We found that two primary colorectal tumour lines, after being maintained in vitro for a few weeks, expressed HLA-DR in response to IFN-y to a greater degree. These observations would tend to support the hypothesis that local factors within the tumour environment limit the responsiveness of the tumour cells to cytokines, and this hyporesponsiveness may permit the tumour cells to escape both non-MHC restricted and MHC restricted lymphocyte killing, and in doing so confer a growth and metastatic advantage. This may have implications when deciding whether adjuvent therapy, possibly with cytokines, should be offered to these patients.
We are grateful to the Cancer Research Campaign for financial support.
